Author:
Dicembrini Ilaria,Tomberli Benedetta,Nreu Besmir,Baldereschi Giorgio Iacopo,Fanelli Fabrizio,Mannucci Edoardo,Monami Matteo
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference30 articles.
1. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;New Engl J Med,2017
2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;New Engl J Med,2018
3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;New Engl J Med,2015
4. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet (London, England),2018
5. Moher D, Liberati A, Tetzlaff J, Altman DGJAoim. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. 2009;151:264–9.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献